BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects financial instability with a net loss and increased R&D expenses, despite a slight revenue increase. The Q&A highlights management's lack of transparency and potential risks in partnerships and supply chains. While there is optimism about market trends and product launches, the financial and operational uncertainties, reliance on preclinical data, and vague responses suggest a negative sentiment, likely leading to a stock price decline.
Key Financial Performance
Revenue $0.5 million for Q1 2026, an increase of $0.2 million (66.67%) compared to $0.3 million in Q1 2025. The increase reflects higher royalties from the commercialization of APHEXDA.
Research and Development Expenses $2.5 million for Q1 2026, an increase of $0.9 million (56.25%) compared to $1.6 million in Q1 2025. The increase was primarily due to expenses related to the new GLIX1 project.
General and Administrative Expenses $0.9 million for Q1 2026, a decrease of $0.1 million (-10%) compared to $1 million in Q1 2025. The decrease was primarily due to reduced legal expenses and other general administrative costs.
Net Nonoperating Income $0.5 million for Q1 2026, a decrease of $7.1 million (-93.42%) compared to $7.6 million in Q1 2025. The decrease was primarily due to noncash fair value adjustments of warrant liabilities influenced by changes in the company's share price, offset by warrant offering expenses.
Net Loss $2.6 million for Q1 2026 compared to a net income of $5.1 million in Q1 2025. The shift to a net loss was influenced by the decrease in nonoperating income and increased R&D expenses.
Cash and Equivalents $17.4 million as of March 31, 2026, sufficient to fund operations into the first half of 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GLIX1: Initiated Phase I/IIa trial for glioblastoma (GBM) and other cancers. First patient dosed at NYU Langone Health. Trial involves 3 academic centers and may expand. Phase I aims to recruit 30 patients to establish maximum tolerated dose and preliminary efficacy. Phase IIa will include additional indications and combinations with standard care. GLIX1 is an oral molecule targeting DNA damage repair in cancer cells, showing promise in preclinical GBM models.
Motixafortide: Continued development in pancreatic cancer (PDAC) through a Phase IIb trial in combination with PD-1 inhibitor and standard chemotherapies. Interim analysis expected later this year.
APHEXDA: Generated $2.5 million in Q1 2026 sales, up from $1.4 million in Q1 2025. BioLineRx received $0.5 million in royalties. Positioned as part of the multiple myeloma treatment paradigm.
Glioblastoma Market: Addressable market for GBM treatments in the U.S. and Europe is estimated at $3.7 billion by 2030, with an annual incidence of 18,500 patients in the U.S. and 13,500 in Europe.
Financial Performance: Q1 2026 revenues increased to $0.5 million from $0.3 million in Q1 2025, driven by APHEXDA royalties. R&D expenses rose to $2.5 million due to GLIX1 project. Net loss for Q1 2026 was $2.6 million, compared to net income of $5.1 million in Q1 2025. Cash reserves at $17.4 million, sufficient until H1 2027.
Ayrmid Out-Licensing Agreement: BioLineRx retains rights to develop motixafortide in PDAC and supports Ayrmid's development of motixafortide in sickle cell disease. Ayrmid holds commercialization rights for APHEXDA and other indications outside Asia.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical trial risks for GLIX1: The Phase I/IIa trial for GLIX1 involves uncertainties related to establishing a maximum tolerated dose, safety, PK/PD, and preliminary efficacy. There is also a risk of delays or challenges in recruiting patients across the three academic centers and potential additional sites.
Regulatory and development risks for GLIX1: The development of GLIX1 for glioblastoma and other cancers faces regulatory hurdles and the need for successful demonstration of efficacy and safety in clinical trials. Failure to meet these requirements could impact the drug's advancement.
Market competition for glioblastoma treatments: Although the glioblastoma market is described as having few competitors, there is still a risk of emerging competition or alternative therapies that could impact the market potential of GLIX1.
Dependence on preclinical data for GLIX1: The advancement of GLIX1 relies heavily on preclinical data, which, while promising, may not translate into successful clinical outcomes.
Financial risks: The company reported a net loss of $2.6 million for Q1 2026, compared to net income in the previous year. This financial performance could impact its ability to sustain operations and fund ongoing projects.
Supply chain and manufacturing risks for motixafortide: The development of motixafortide for sickle cell disease and other indications requires reliable production of large quantities of stem cells, which could strain already constrained apheresis capacity.
Dependence on partnerships: The company’s reliance on partnerships, such as with Ayrmid for the commercialization of APHEXDA and development of motixafortide, poses risks if these partnerships face challenges or fail to deliver expected outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
GLIX1 Clinical Development: The Phase I/IIa trial for GLIX1, targeting glioblastoma (GBM) and other cancers, has been initiated. Phase I aims to recruit up to 30 patients to establish a maximum tolerated dose and preliminary efficacy, with updates expected in the second half of 2026 and full results in 2027. Phase IIa will expand to include newly diagnosed GBM and other cancers, exploring GLIX1 as monotherapy or in combination with standard care, including PARP inhibitors.
Market Potential for GLIX1: By 2030, the annual incidence of GBM is projected to reach approximately 18,500 patients in the U.S. and 13,500 in Europe, representing a total addressable market of over $3.7 billion in these regions.
Pancreatic Cancer (PDAC) Development: The randomized Phase IIb trial, CheMo4METPANC, evaluating motixafortide in combination with cemiplimab and standard chemotherapies, is progressing well. An interim futility analysis is anticipated later in 2026.
APHEXDA Growth: APHEXDA sales are growing, with $2.5 million in Q1 2026 compared to $1.4 million in Q1 2025. The company anticipates continued growth in its role within the multiple myeloma treatment paradigm.
Sickle Cell Disease Development: Ayrmid is advancing motixafortide development for sickle cell disease, addressing the unmet need for effective stem cell mobilization agents. This could contribute to future revenues.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are your thoughts on the current development landscape in GBM and how challenging or competitive it is to enroll patients in this population?
A:The GBM development landscape is wide open with limited effective treatments available. There are some medical devices like the TT fields device, but in terms of biologics or pharmaceuticals, there is not much competition. Recruitment for the current study in recurrent and progressive GBM patients is not expected to face significant challenges.
Q:Could you provide an update on activation status at Northwestern and Moffit? Are all 3 centers now open and screening and enrolling patients?
A:The company has not disclosed the status of each site. NYU is up and recruiting, and the other sites are expected to open very shortly.
Q:Now that the first patient has been dosed with GLIX1, are there any initial safety observations you're able to share?
A:No specific safety observations were disclosed. The company plans to provide periodic updates but has no information to share at this time.
Q:What are the anticipated next steps and conclusion timeline for the CheMo4METPANC trial?
A:An interim futility analysis is expected later this year when 40% of the PFS events occur. The company is evaluating signals to support CXCR4 inhibition as a backbone agnostic adjunctive strategy, considering potential changes in the treatment paradigm over the next few years.
Q:Can you provide metrics or details about Ayrmid's efforts with APHEXDA, such as regions covered, sales professionals, payer coverage, marketing budget, and digital strategies?
A:The company did not provide detailed metrics or guidance on Ayrmid's efforts. However, it was noted that APHEXDA sales increased significantly from $1.3-$1.4 million last year to $2.5 million this year, indicating positive progress.
Q:What dose level do you think would be the absolute maximum in the GLIX1 clinical trials?
A:The company has not disclosed the doses to be used in the clinical trials. However, preclinical data showed a dose of up to 2,000 mg/kg in rats, providing a significant safety margin compared to expected clinical doses.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or sufficient details for several questions, including the activation status of Northwestern and Moffit, initial safety observations for GLIX1, Ayrmid's detailed efforts with APHEXDA, and the maximum dose levels for GLIX1 clinical trials. Responses were vague or withheld due to trade secrets or lack of disclosure.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APHEXDA
Center
Dr
GBM cancer
GLIX
Langone Health
PD
Phase
TET activity
abstract
addition
agent
brain
cash
cell
development
dose
effect
income month
increase month
increase revenue
indication
inhibition
model GBM
molecule
month income
month increase
motixafortide
need
patient
standard care
survival
temozolomide
treatment
trial
tumor
week
xenograft
BLRX Transcript
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
Unknown5-27
The earnings call reflects financial instability with a net loss and increased R&D expenses, despite a slight revenue increase. The Q&A highlights management's lack of transparency and potential risks in partnerships and supply chains. While there is optimism about market trends and product launches, the financial and operational uncertainties, reliance on preclinical data, and vague responses suggest a negative sentiment, likely leading to a stock price decline.
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
Unknown3-23
The earnings call lacks detailed financial metrics, revenue, or margin updates, leading to uncertainty. The strategic initiatives and market trends are positive, but the absence of explicit guidance and financial details, coupled with acknowledged risks, tempers optimism. The Q&A section does not provide additional clarity, reinforcing a neutral sentiment.
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
Unknown11-24
The earnings call reveals several concerns: delayed revenue from trials, financial dependency on a single product, and limited cash reserves. The Q&A section highlights management's evasiveness on key metrics, further increasing uncertainty. Despite reduced losses and operational cost cuts, the company's reliance on royalties and uncertain trial outcomes are significant risks. These factors suggest a negative sentiment towards the company's short-term stock performance.
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
Unknown8-14
Despite a strong partnership with Ayrmid Pharma and reduced operating costs, the company faces risks such as slow APHEXDA adoption and a significant net loss. The Q&A revealed cautious optimism with positive feedback on ASCO data but uncertainty around asset acquisition and study timelines. The neutral rating reflects balanced prospects, with financial sustainability dependent on future milestones.
BLRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
